Publications

5543 Results

TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy

Authors
A Bardia;L Pusztai;K Albain;E Ciruelos;S Im;D Hershman;K Kalinsky;C Isaacs;D Loirat;L Testa;E Tokunaga;J Wu;H Dry;W Barlow;R Kozarski;M Maxwell;N Harbeck;P Sharma
Journal / Conference
Therapeutic Advances in Medical Oncology Apr 29:16:17588359241248336
Year
2024
Research Committee(s)
Breast
PMID
PMID38686016
PMC
PMC11057345

A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol

Authors
J Neal;K Minichiello;R Brennick;R Huang;M Hiemenz;C Amler;J Patel;R Herbst;K Reckamp;H Borghaei;L Highleyman;M Redman;L Pasquina;D Kozono
Journal / Conference
Oncologist Jun 3;29(6):e843-e847
Year
2024
Research Committee(s)
Lung
PMID
PMID38597608
PMC
PMC11144964
Study Number(s)
LUNGMAP

Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study

Authors
M Allaf;S Kim;V Master;D McDermott;L Harshman;L Harshman;S Cole;C Drake;S Signoretti;S Signoretti;M Akgul;N Baniak;E Li-Ning;M Palmer;H Emamekhoo;N Adra;H Kaimakliotis;Y Ged;P Pierorazio;E Abel;M Bilen;K Ogan;H Moon;K Ramaswamy;E Singer;T Mayer;J Lohrey;V Margulis;J Gills;S Delacroix;M Waples;A James;P Wang;T Choueiri;M Michaelson;A Kapoor;D Heng;B Shuch;B Leibovich;P Lara;J Manola;D Maskens;D Battle;R Uzzo;G Bratslavsky;N Haas;M Carducci
Journal / Conference
Lancet Oncology Aug;25(8):1038-1052
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID38942046
PMC
PMC11323681
Study Number(s)
CTSU/EA8143

Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials

Authors
C Gallois;Q Shi;L Pedersen;T Andre;T Iveson;A Sobrero;S Alberts;A De Gramont;J Meyerhardt;T George;H Schmoll;I Souglakos;A Harkin;R Labianca;F Sinicrope;E Oki;A Shields;I Boukovinas;R Kerr;S Lonardi;G Yothers;T Yoshino;R Goldberg;J Taieb;D Papamichael
Journal / Conference
Journal of Clinical Oncology Jul 1;42(19):2295-2305
Year
2024
Research Committee(s)
Gastrointestinal
PMID
PMID38547438
Study Number(s)
CTSU/C80702

Comparing the Accuracy of Traditional vs. FHIR®-based Extraction of Electronic Health Record Data for Two Clinical Trials

Authors
M Garza;C Spencer;M Hamidi;M Liss;M Bikkanuri;M Syed;S Yadav;G Bhardwaj;A Chahal;K Goodman;B Choi;E Eisenstein;M Zozus
Journal / Conference
Studies in Health Technology and Informatics Aug 22:316:1368-1372
Year
2024
Research Committee(s)
Multiple sites

Biomarker challenges in the pursuit of personalized neoadjuvant chemotherapy for muscle-invasive bladder cancer: conclusions from SWOG S1314 [Editorial]

Authors
S Kim;M St-Laurent;P Black
Journal / Conference
Translational Andrology and Urology Mar 31;13(3):458-462
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID38590957
PMC
PMC10999026
Study Number(s)
S1314

Lung-MAP Next Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)

Authors
D Kozono;X Hua;M Wu;K Tolba;S Waqar;K Dragnev;H Cheng;FR Hirsch;P Mack;JE Gray;K Kelly;H Borghaei;RS Herbst;DR Gandara;M Redman
Journal / Conference
Journal of Thoracic Oncology Aug 5:S1556-0864(24)00751-2
Year
2024
Research Committee(s)
Lung
PMC
PMID39111731
Study Number(s)
LUNGMAP, S1400

A Genomic Scar Based Signature (HRDsig) and Biallelic BRCA Alterations Identify a Homologous Recombination Deficiency (HRD) Phenotype of Non-Small Cell Lung Cancer (NSCLC) Potentially Actionable to the PARP inhibitor Rucaparib: Post-Hoc Analysis of Lung-MAP Substudy S1900A

Authors
J Riess;J Miao;P Wheatley-Price;K Reckamp;D Kozono;M Redman;M Edelman;B Faller;L Villaruz;L Corum;A Gowda;G Srkalovic;R Osarogiagbon;M Baumgart;D Gandara;E Sokol;H Borghaei;J Gray;R Herbst;K Kelly
Journal / Conference
ESMO Congress (Sept 13-17, 2024, Barcelona Spain, poster; Annals of Oncology (2024) 35 (suppl_2): S802-S877. 10.1016/annonc/annonc1602
Year
2024
Research Committee(s)
Lung
Study Number(s)
S1900A

Final overall survival analysis of S1500: A randomized, phase II study comparing sunitinib to cabozantinib, crizotinib and savolitinib in advanced papillary renal cell carcinoma

Authors
P Barata;C Tangen;M Plets;I Thompson;V Narayan;D George;D Heng;B Shuch;M Stein;S Gulati;A Tripathi;G Bjarnason;U Vaishampayan;A Alva;T Zhang;S Cole;P Lara;N Balzer-Haas;S Lerner;S Pal
Journal / Conference
Journal of Clinical Oncology Nov 20;42(33):3911-3916
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID39255440
Study Number(s)
S1500

Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma

Authors
V Ma;J Moon;J Fruehauf;L Flaherty;M Bury;W Martin;H Gross;W Akerley;J Hopkins;S Patel;V Sondak;A Ribas
Journal / Conference
Cancer Sep 29. doi: 10.1002/cncr.35587. Online ahead of print
Year
2024
Research Committee(s)
Melanoma
PMID
PMID39342463
Study Number(s)
S0826